Ventus to receive $70M up front in cash incl. R&D funding & will also be eligible to receive an additional ~$633M in clinical, regulatory, and commercial milestones along with royalties
Novo Nordisk to get an exclusive right globally to develop & commercialize Ventus’ NLRP3 inhibitor program for diseases, incl. NASH, CKD & other cardiometabolic conditions. Ventus also holds the right to develop NLRP3 inhibitors for systemic diseases incl. specific inflammatory & respiratory diseases and also gets the global rights to the brain-penetrant NLRP3 inhibitor program
The collaboration combines Ventus’ NLRP3 inhibitor program with Novo Nordisk’s deep expertise across cardiometabolic diseases & provides clinical benefit to patients with a broad range of diseases
Ref: Ventus | Image: Novo Nordisk
